Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

AEterna Zentaris Articles

AEterna Zentaris transfers Cetrotide rights to Merck KGaA

18 April 2013

Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108

10 April 2013

AEterna Zentaris slides as it discontinues perifosine in myeloma

12 March 2013

AEterna Zentaris' perifosine seen as potential novel approach for mesothelioma

31 May 2012

News briefs: Roche's dalcetrapib; Coherus/Daiichi deal; Mercury Pharma; AEterna Zentaris

8 May 2012

AEterna Zentaris and Keryx shares tank as cancer drug flops in Ph III

3 April 2012

Highlights of ASH meeting

13 December 2011

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region

24 November 2011

Regeneron/Sanofi colorectal cancer drug Zaltrap will see peak-year sales of up to $250 million

13 May 2011

Yakult Honsha in 50 million-euro deal to market AEterna Zentaris’ perifosine in Japan

10 March 2011

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS